Streptocinaza (streptokinase) infusions 1 500 000 IU №1 vial


Acute coronary syndrome with persistent ST-segment elevation or recent left-sided blockade of the atrioventricular bundle, acute myocardial infarction with a Q tooth – no later than 12 hours after the onset of the disease (treatment may not be predicted after administration of the aforementioned period). Massive deep vein thrombosis at risk of gangrene. Pulmonary embolism. Acute, subacute and chronic peripheral artery thrombosis with ischemia risk. Thrombosis of the central artery or central vein of the retina.



Composition and form of release
The active ingredient is streptokinase. It is produced in the form of a powder, which is the main one for the preparation of injections for intravenous drip, sometimes intra-arterial injection.
Produced in bottles with different dosages –  1,500,000 IU (unit of measurement of the dose of the substance).
It is prescribed for the treatment of embolism (blockage) of the pulmonary artery and its branches. Treatment of thrombosis (formation of a blood clot in a vessel) of arteries, blockage (embolism) of peripheral arteries, vein thrombosis (both deep and close to the skin). Effective in the treatment of acute myocardial infarction in the first 12 hours, blockage of the vessels of the mesh.
Able to activate the fibrinolytic (that is, able to dissolve blood clots) enzyme system, to break down fibrin, which is contained in blood clots, thereby dissolving the blood clot that clogged the vessel (thrombolysis phenomenon).
It is forbidden to use for hemorrhagic diathesis, fresh bleeding, high and pressure, streptococcal sepsis, stomach ulcers, septic endocarditis, severe diabetes mellitus. It should be carefully prescribed for severe liver and kidney damage, tuberculosis in the active phase.
Application during pregnancy and lactation
Do not use in the first 18 weeks of pregnancy and with poor blood clotting in women.
Method of administration and dosage
Streptokinase is injected drip (intravenously, intraarterially), dissolving in a solution of sodium chloride. They start with a small dose (250 thousand IU) per 50 ml of solution, within 30 minutes. After that, lysis begins (the process of dissolution of a thrombus). After that, 100 thousand are administered per hour, for 16-18 hours.
The drug is injected into the artery with susprominfarct, starting from 20 thousand.
The earlier the treatment with Streptokinase begins, the faster and more efficiently the clot dissolves. It is undesirable to use if myocardial infarction began more than 24 hours. Deep vein thrombosis – 2 weeks, retinal artery thrombosis – 6-8 hours, retinal veins – 10 days or more, endarteritis obliterans – 6 weeks.
During and after the procedure, it is necessary to monitor the patient’s thrombin time (blood clotting rate), the content of neufibrinogen.
Unlikely. Can theoretically cause a decrease in the patient’s blood clotting.
Side effects
An unusual reaction to protein may occur: nausea, chills, bruising. To prevent such reactions, it is recommended to administer prednisolone (50 mg).
Storage conditions and periods
Lyophilisate Streptokinase is able to retain its medicinal properties for up to 5 years, subject to storage conditions – out of direct sunlight and ambient temperature up to + 25 ° C. The prepared solution is stored for no more than 12 hours.